2024年7月31日 · Treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an...

Learn about CARVYKTI®, a type of CAR-T cell therapy for adult patients. See Safety & Prescribing information, including Boxed Warning. CARVYKTI ® (ciltacabtagene autoleucel) is …

2022年3月30日 · FDA has approved ciltacabtagene autoleucel (Carvykti) for adults with multiple myeloma that is not responding to treatment or has returned after treatment.

Ciltacabtagene autoleucel, sold under the brand name Carvykti, is an anti-cancer medication used to treat multiple myeloma. [8] [10] [12] [13] Ciltacabtagene autoleucel is a BCMA (B-cell …

2024年4月6日 · CARVYKTI ® (cilta-cel) received U.S. Food and Drug Administration approval in February 2022 for the treatment of adults with relapsed or refractory multiple myeloma after …

Learn about CARVYKTI®, including what it is, how it works, patient response in a clinical study, safety, and more. See Safety & Prescribing info, including Boxed Warning.

2024年7月5日 · CARVYKTI ® (ciltacabtagene autoleucel) is a BCMA-directed genetically modified autologous T cell immunotherapy. CARVYKTI is prepared from the patient's peripheral blood …

FDA approved ciltacabtagene autoleucel (CARVYKTI, Janssen Biotech, Inc.) for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of...

Carvykti (ciltacabtagene autoleucel) is a CAR-T therapy used to treat relapsed or refractory multiple myeloma (RRMM). It is an autologous cell therapy, meaning it is made from the …

CARVYKTI® is a B-cell maturation antigen (BCMA)–directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory …